











Regional cooling of the extracorporeal blood
circuit: a novel anticoagulation approach
for renal replacement therapy?
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Abstract Objective: To test the
hypothesis that cooling of blood in
the extracorporeal circuit of continu-
ous veno-venous hemofiltration
(CVVH) enables to realize the pro-
cedure without the need of
anticoagulation. Design: Experi-
mental animal study. Methods: We
developed the device for selective
cooling of extracorporeal circuit
(20C) allowing blood rewarming
(38C) just before returning into the
body. Twelve anesthetized and ven-
tilated pigs were randomized to
receive either 6 h of CVVH with
application of this device (COOL;
n = 6) or without it (CONTR;
n = 6). Measurements: Before the
procedure and in 15, 60, 180,
360 min after starting hemofiltration
variables related to: (1) circuit
patency [time to clotting (TC), num-
ber of alarm-triggered pump stopping
(AS), venous and transmembranous
circuit pressures (VP, TMP)], (2)
coagulation status in the extracorpo-
real circuit [thrombin-antithrombin
complexes (TATcirc), thromboelas-
tography (TEG)] and (3) animal
status (hemodynamics, hemolysis and
biochemistry) were assessed.
Results: The patency of all circuits
treated with selective cooling was
well maintained within the observa-
tion period. By contrast, five of six
sessions were prematurely clotted in
the untreated group. As a result, the
number of AS was significantly
higher in the CONTR group. In-cir-
cuit thrombus generation in CONTR
group was associated with a markedly
increasing TATcirc. TEG performed at
180 min of the procedure revealed a
tendency to a prolonged initial clot-
ting time and a significant decrease in
clotting rate of in-circuit blood in the
COOL group. No signs of repeated
cooling/rewarming-induced hemoly-
sis were observed in animals treated
with ‘‘hypothermic circuit’’ CVVH.
Conclusion: In this porcine model,
regional extracorporeal blood cooling
proved effective in preventing in-cir-
cuit clotting without the need to use
any other anticoagulant.
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Introduction
A contact of blood with synthetic materials of the extra-
corporeal circuit results in the activation of coagulation
[1]. Therefore, renal replacement therapy use in the crit-
ically ill usually requires administration of anticoagulants.
The most common way of preventing blood from clotting
is systemic administration of anticoagulants, which,
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however, is not feasible in at risk patients. In these cases,
alternative methods are often used including regional
anticoagulation, minimal heparinization, use of prosta-
glandins or circuit saline flushes at regular intervals [2, 3].
Unfortunately, none of these methods is optimal, as it is
costly, inadequately effective, or associated with meta-
bolic risks [2].
Lowering blood temperature is known to reduce
blood clotting [4, 5]. This effect is mainly due to inhi-
bition of enzymatic reactions of the coagulation cascade
and to impaired platelet function [6, 7]. The lower blood
temperature, the more appreciable the effect [5]. On the
other hand, blood rewarming seems to normalize the
coagulation defect [8]. This has led to a hypothesis
under which, if the temperature of the blood in the
extracorporeal circuit could be reduced adequately and
rewarmed accordingly prior to returning it back to the
patient’s body, there would be no need for anticoagu-
lation at all.
We therefore conducted an experimental study
designed to determine whether cooling of blood in CRRT
extracorporeal circuit to 20C with its subsequent
rewarming to baseline temperature before returning it to
the body will allow performing an extracorporeal proce-
dure without anticoagulant use.
Methods
The experiment was performed in compliance with the
National Institutes of Health Guidelines on the Use of
Laboratory Animals. The study protocol was approved by
the University Animal Care Committee.
Animals and preparations
Twelve domestic pigs with a comparable body weight [37
(33; 43) kg] were investigated. Anesthesia was induced
with i.v. atropine (0.5 mg), propofol 2% (1–2 mg/kg) and
ketamine (2 mg/kg). Animals were mechanically venti-
lated (FiO2 0.4, PEEP 5 cm H2O, tidal volume 10 ml/kg,
respiratory rate adjusted to maintain end-tidal PCO2
between 4.0 and 5.0 kPa). During instrumentation, sur-
gical anesthesia was maintained with continuous
intravenous thiopental [10 mg/(kg h)] and repeated
boluses of buphrenorphine (0.3 mg). Thereafter, contin-
uous thiopental [5 mg/(kg h)] was maintained until the
end of the experiment and buphrenorphine (0.3 mg) was
added every 3 h to prevent inadequate analgesia. Muscle
paralysis was achieved with pancuronium [0.2 mg/
(kg h)]. Infusion of Plasma Lyte solution (Baxter
Healthcare) of 10 ml/(kg h) was administered during the
instrumentation and subsequently reduced to 5 ml/(kg h)
as a maintenance fluid.
A 14 Fr double-lumen hemodialysis catheter of 15 cm
length (Arrow International, Inc.; Reading, USA) was
inserted via the right femoral vein. The left femoral artery
was cannulated by a fiberoptic catheter equipped with a
thermistor for blood pressure recording, blood sampling,
continuous blood temperature recording, and thermal-dye
double-indicator dilution measurements. A cystostomy
catheter for urine derivation was placed percutaneously
under ultrasound guidance. A post-instrumentation sta-
bilization period of 1 h was allowed before baseline
measurements were obtained.
CRRT setting
CRRT was performed in a continuous hemofiltration
mode (CVVH, MultiFiltrate, Fresenius Medical Care AG
& Co. KGaA, Bad Homburg, Germany) using a poly-
sulfone membrane (Ultraflux AV600S, Fresenius Medical
Care AG & Co. KGaA, Bad Homburg, Germany). Blood
flow rate was set at 150 ml/min. A lactate-buffered
replacement fluid (Medisol K4, solution for hemofiltra-
tion, Medites Pharma, Roznov pod Radhostem, Czech
Republic) was administered in a post-dilutional fashion.
The treatment was zero-balanced at an ultrafiltration rate
20 ml/(kg h). To avoid a possible effect of ultrafiltration-
mediated changes in measured variables, the substitution
and ultrafiltration pumps were temporarily switched off
5 min before every blood sampling.
Cooling device
Technical schema of the cooling device is shown in Fig. 1.
The device was developed in our institution and is cur-
rently patent pending (provisional patent number PV
2008–35). Briefly, the device comprises a cooling unit
placed under the CRRT system and a second, warming,
unit placed behind it. The first heat exchanger is connected
to a tube bringing in the cooling medium, while the other is
connected to a tube bringing in a heating medium. The
temperature in both exchangers can be set across a wide
range. In our project, the temperature of the blood at the
inflow tract of the extracorporeal circuit was set at 20C
while raising it to the baseline body core temperature on
the return. The system is fitted with thermal needle sen-
sors, introduced into the circuit via several sampling ports
to check whether the preset temperature has been reached.
Before each experiment, the sensors were tested using the
calibration device Techne TECAL 140H to check their
accuracy. Data from the sensors are continuously trans-
mitted to a computer control unit, automatically adjusting,
by a feedback mechanism, the process of cooling and
warming both via a change in the cooling/heating medium
temperature and change in the rate of medium flow
through the heat exchanger.
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Protocol and measured parameters
Twelve pigs were randomized to undergo either 6 h of
‘‘hypothermic circuit’’ CVVH (COOL; n = 6) or ‘‘iso-
thermic circuit’’ CVVH (CONTR; n = 6). Before the
beginning of CVVH as well as 15, 60, 180, 360 min after its
start, variables related to circuit patency (time to clotting,
number of alarm-triggered pump stopping, circuit’s venous
and transmembranous pressures) were recorded. In addi-
tion, parameters of coagulation status in the extracorporeal
circuit (thrombin–antithrombin complexes measured at 15,
60, 180, 360 min (Enzygnost TAT micro, Behringwerke
AG, Marburg, Germany), thromboelastography [measured
at 180 min (TEG5000 Thromboelastograph Hemostasis
Analyzer, Haemoscope, USA)] and markers of safety of the
method (hemodynamic status, body core temperature,
blood count, free plasma hemoglobin, bilirubin and liver
enzymes, blood gases) were measured. The TEG mea-
surements were performed at the same temperature as was
the temperature in the extracorporeal circuit (i.e. at 20C in
‘‘hypothermic’’ circuit group, at 38C in ‘‘normothermic’’
circuit group).
Statistical analysis
All values shown are median and interquartile range.
Differences within each group during CVVH were tested
using a Friedman ANOVA on ranks. Differences between
the groups were analyzed using Mann–Whitney analysis.
Fig. 1 Technical schema of the
cooling device. D CRRT
machine (CVVH mode), V1
cooling unit, V2 warming unit,
P1 unit for cooling of the
medium, P2 unit for heating of
the medium, C pump, T1–T5
thermal sensors, R computer




Animals in both groups did not differ in any of the
measured variables at baseline.
Circuit patency
The patency of all circuits treated with selective cooling
was well maintained within the observation period. By
contrast, five of six sessions were prematurely clotted in
the untreated group [time to clotting 197 (180; 240) min].
As shown in Table 1, progressive circuit obstruction in
the control group was accompanied by increasing circuit
venous and transmembranous pressures, whereas these
variables remained unchanged during the entire session in
the COOL group. As a result, the number of pressure
alarm-triggered pump stopping was significantly higher in
the control group [CONTR 6 (5; 7) vs. COOL 1.5 (0; 2),
P = 0.015].
Coagulation status in the extracorporeal circuit
The early clotting of the extracorporeal circuit observed
in the CONTR group was associated with a progressive
increase in thrombin–antithrombin complexes (TATcirc),
suggesting ongoing in-circuit thrombin generation
(Table 1). By contrast, the rise in TATcirc was less
obvious in the COOL group. Concerning the dynamics of
in-circuit clot formation, data obtained from thrombo-
elastography (TEG) at 180 min of the procedure revealed
a tendency to a prolonged initial clotting time (R) and a
significant decrease in clotting rate (K, a angle) in the
COOL group (Table 2), without affecting clot strength
(MA). Representative TEG tracings are shown in Fig. 2.
Animal status and biochemistry
During the whole study period all animals in both groups
remained hemodynamically stable with unchanged base-
line body core temperature. The number of platelets
decreased significantly in both groups without any inter-
group differences (Table 3). We did not observe any
alterations in liver enzymes and blood gases (data not
shown). In addition, no signs of repeated cooling/
rewarming-induced hemolysis in serial free plasma
hemoglobin measurements were observed in two
Table 1 In-circuit pressures and thrombin–antithrombin complexes
Variable Group 15 60 180 360
VP (mmHg) COOL 110 (88; 122) 100 (78; 158) 80 (80; 125) 80 (80; 205)
CONTR 140 (110; 180) 265a,b (200; 360) 360a,b (315; 418) –
TMP (mmHg) COOL 10 (8; 10) 10 (8; 10) 10 (10; 28) 20 (10; 48)
CONTR 1 (1; 20) 5b (1; 10) 30b (20; 285) –
TAT circ (lg/l) COOL 14 (9; 23) 44b (37; 49) 70b (47; 141) 104b (47; 110)
CONTR 30a (21; 37) 78b (57; 92) 174b (121; 192) –
VP venous pressure, TMP transmembranous pressure, TAT thrombin–antithrombin complexes
a P \ 0.05 versus COOL
b P \ 0.05 versus 15
Table 2 In-circuit thromboelastography
Parameter Group
COOL CONTR
R (min) 19 (10.4; 19.8) 7.5 (1.4; 14.1)
K (min) 7.9 (6.3; 9.4) 3.6a (1.8; 5.5)
a angle () 31 (26; 34) 52a (37; 67)
MA (mm) 77 (75; 81) 72 (54; 77)
R time from initiation of the test to the initial fibrin formation, K
time from beginning of clot formation until the amplitude reaches
20 mm (represents dynamics of clot formation), a angle between
the line in the middle of the TEG tracing and the tangential to the
‘‘body’’ of the TEG tracing (represents the kinetics of fibrin build
up and cross-linking), MA the rate of amplitude reduction 60 min
after MA (represents the stability of the clot)
a P \ 0.05 versus COOL
Fig. 2 Representative TEG tracings. a Hypothermic extracorporeal
circuit. b Isothermic extracorporeal circuit
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randomly selected animals treated with ‘‘hypothermic
circuit’’ CVVH (Fig. 3).
Discussion
The main result of our experimental study is that regional
cooling of blood in the CRRT extracorporeal circuit to
20C for 6 h makes it possible to perform the procedure
without the need to use any anticoagulant with no blood
clotting in the extracorporeal circuit.
Admittedly, our idea to use regional blood cooling in a
RRT method is not completely new. This method has
been employed in an experimental setting whereby pigs
underwent 3-h intermittent dialysis with blood in the
circuit also cooled to 20C and rewarmed to 37C, using a
microwave oven, before returning it to the animals’ body
[9]. However, that study was focused rather on assessing
changes in biocompatibility (C5a) of intermittent dialysis
modified in this manner while not seeking to monitor in
detail changes in blood clotting and dynamics of throm-
bus formation within the circuit. Despite this, consistent
with our results, the authors noted that the use of cooling
allowed them to perform this relatively short procedure
without in-circuit blood clotting. However, the device we
have developed has a number of different features. First, it
was a device intended for CRRT, i.e., a method operating
at lower blood flow rates potentially associated with
enhanced coagulation activation. Second, the technique of
blood rewarming on return was quite different in our case
(not a microwave oven but a heat exchanger, which we
consider biologically safer). Moreover, using a computer,
its efficacy was controlled by feedback ruling out inade-
quate warming of returning blood.
The explanation why extracorporeal circuit cooling
helps maintain its patency with no blood clotting can be
found in data regarding thrombin generation and its in-
circuit dynamics. These data revealed that blood cooling
led primarily to inhibition of the initiation phase of
thrombin generation consequently compromising the
clotting process. The result was both a delay in the ini-
tiation of thrombus formation and a decrease in the rate of
thrombus growth. Still, the strength of a thrombus formed
in this way did not differ from that of a normal thrombus,
which is a finding consistent with that reported from other
studies [10]. Moreover, our results are in accordance with
data published by Martini, who studied the effect of body
hypothermia on coagulation in the pig [11, 12]. The role
of platelet count and platelet dysfunction should also be
taken into consideration when interpreting our findings.
We observed a decrease in platelet count in both groups
during the procedure. However, the rate of decrease did
not differ between the groups and it should be noted that
platelet count remained well within the physiological
range, so this mechanism should not have affected the
process of thrombus formation and altered its strength.
Although platelet functions were not assessed in our
experimental study, available data suggest that hypo-
thermia may have a major impact on platelet functions,
which, in turn, may have contributed to the anticoagula-
tion effect of cooling seen in our study [6, 13].
The key issue that should be further addressed is
whether multiple repetition of the process of cooling/
rewarming could have undesirable effects. It should be
noted, however, that our study was not primarily designed
to evaluate potential side effects, but, in the first place, to
demonstrate the system functionality. To analyze the
Table 3 Hemodynamics, core temperature and platelet count
Variable Group Before After
































MAP mean arterial pressure, CO cardiac output, T core tempera-
ture, PLT platelets
a P \ 0.05 versus before
Fig. 3 Free hemoglobin in arterial plasma
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safety of the system, which is undoubtedly essential,
would require a comprehensive approach at the levels of
both cellular and non-cellular blood components (pro-
teins, enzymes, immune system, etc.) Nevertheless, we
can exclude clinically relevant hemolysis as serial free
plasma hemoglobin did not change during the study. One
might argue that data on free hemoglobin were obtained
from two animals only. However, given their consistency
and stability we do not think that getting more data from
additional animals would change the picture substantially.
In addition, none of the animals showed an increase in
bilirubin and lactate dehydrogenase or a decrease in
erythrocyte count (data not shown), further making the
possibility of hemolysis unlikely.
Data regarding changes in the properties of blood ini-
tially cooled and subsequently rewarmed in terms of its
ability to clot are scarce. It is known that blood rewarming
results in reversal of coagulation defect [14] and rewarming
a patient with hypothermic coagulopathy is a routine ther-
apeutic intervention [15]. Likewise defect in platelets
aggregation reversed after protracted hypothermia in a
canine model [16]. However, none of these situation closely
mimics the course of our experiment whereby cooling/
rewarming occurred after each passage of blood through the
device and kept on repeating for a number of hours.
Our study has several limitations. Although testing our
device in CVVH, it was not used for more than 6 h. Still,
upon completion of procedures involving blood cooling
and after flushing the extracorporeal circuit with saline, we
noted only minimal signs of clotting; the median of sings
of clotting was 2 (using a 1–5 scale where 5 indicated
complete clotting and 1 an absolutely clean system with-
out any thrombi at all). As a result, a procedure handled in
this manner could probably last for many more hours.
Although similarities in the human and the porcine
coagulation and fibrinolytic systems have been reported
[17, 18], this fact should be taken into consideration in this
context. In addition, our study was performed in healthy
animals, but many critically ill patients scheduled for
CRRT show a more or less pronounced coagulation
abnormality. Therefore, given the current state of knowl-
edge, we are unable to extrapolate the function of our
device to those conditions. Similarly, the selection of
temperature in the extracorporeal circuit was more or less
empirical. The intention was to decrease the temperature
to a level low enough, in the experience of other authors, to
prevent blood from clotting [9, 13]. Judging from our
results, decreasing temperature to 20C is enough to obtain
the desired effect; however, we are unable to say whether
identical efficacy could have been obtained with a higher
temperature (which would presumably also entail lower
technical requirements on the device).
In summary, the method of selective in-circuit blood
cooling seems to be a feasible alternative strategy for
anticoagulation during CRRT, at least within this exper-
imental setting. The crucial step for making it clinically
applicable is to demonstrate its safety. Should this hap-
pen, then incorporation of the device into CRRT systems
should become a technical challenge.
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